Oxford Covid biotech firm makes stellar debut on London stock market
by Julia Kollewe from Science | The Guardian on (#5Q6FF)
Shares of Oxford Nanopore close up 44%, giving co-founder paper fortune of 63m
Oxford Nanopore, whose DNA sequencing technology has been essential in tracking Covid-19 variants globally, has made a stellar stock market debut in London. A rise in its share price of as much as 47% has left the firm valued at almost 5bn.
The flotation of the Oxford University spin-out has given its chief executive and co-founder, Gordon Sanghera, a fortune on paper of 63m.
Continue reading...